Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

190
Citadel's Bet Avrobio Does Not Suit Me At The Moment

2018-06-16 seekingalpha
Morgan Stanley, Cowen, Wells Fargo and Wedbush Pacgrow will help the company sell 22,313,687 shares at $16-$18 per share.
WFCNP MS.PRE WFC.PRL MS.PRF WFC.PRJ MS.PRG MS.PRA ONCE WFC.PRT SHPG MYL WFC.PRR WFC.PRQ SLN WFC.PRP WFC.PRO WFC.PRN WFC.PRY MS WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS EPIX VBIV SNY BMRN ARDX MS.PRI EPI MS.PRK NVS PLX PFE

60
Protalix BioTherapeutics: What The Latest Data For OPRX-106 Foretells

2018-06-13 seekingalpha
Protalix is innovating a novel approach to enzyme replacement therapy and other protein therapeutics based on the plant cells manufacturing system.
PLX

83
PLX / Protalix BioTherapeutics, Inc. FORM S-8

2018-06-08 sec.gov
Registration No. 333-_______
PLX

90
Cheniere Energy Partners downgraded to neutral from overweight at J.P. Morgan

2018-05-15 marketwatch
Cheniere Energy (LNG) saw three upward target price revisions following its 1Q18 earnings. These changes could be due to an increase in its 2018 guidance.
TRP CQP CLMT LNG MS.PRE MS.PRF MS.PRG NEP MS.PRA MS.PRI MS.PRK NYLD CQH MS PLX NYLD.A

198
Grace Board Elects Yanai Independent Director

2018-05-09 globenewswire
COLUMBIA, Md., May 09, 2018 (GLOBE NEWSWIRE) -- W. R. Grace & Co. (NYSE:GRA) today announced that its Board of Directors has elected Shlomo Yanai as an independent director.
TEVJF GRA TEVA TEVVF PLX CBM

59
Protalix BioTherapeutics' (PLX) CEO Moshe Manor on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Good day, ladies and gentlemen, and welcome to the Protalix BioTherapeutics First Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a Q&A session and instructions will follow at that time. [Operator Instructions]. As a reminder, this conference is being recorded. I would now like to introduce your host for today's conference Mr. Yossi Maimon, Chief Financial Officer, you may begin.
PLX

203
PDL Biopharma: Activist Investor, Enter Stage Right

2018-04-27 seekingalpha
Despite having risen nearly 50% from 2017 lows of $2, PDLI biopharma (PDLI) remains undervalued, and activist investors are starting to notice. Recent activist behavior from SevenSaoi Capital could act as yet another catalyst for PDL’s price to increase towards book value of $5.84, nearly 110% higher than the current price of $2.9.
SGNT TEVA PLX PDLI CBM

140
Rounds Report: Crispr Rallied While FDA Developments Could Benefit Gene-Based Innovators

2018-04-20 seekingalpha
Shares of Crispr continued to trade further North. The management is gearing up the next growth phase by streamlining its team.
GILD SLDB SGMO CRSP RARE FOLD XBI ONCE RGNX ATRA IBB PLX

74
PLX / Protalix BioTherapeutics, Inc. DEFA14A

2018-04-18 sec.gov
UNITED STATES<
PLX

77
PLX / Protalix BioTherapeutics, Inc. FORM 8-K (Current Report)

2018-04-16 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
PLX

PLX : Protalix BioTherapeutics Stock Analysis and Research Report

2017-10-02 - Asif

Protalix BioTherapeutics is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx® protein expression system, or ProCellEx. The company developed its first commercial drug product, ElelysoTM, using its ProCellEx system and The company is now focused on utilizing the system to develop a pipeline of proprietary, clinically superior versions of recombinant therapeutic proteins that primarily target large, established pharmaceutical markets and that in most cases rely upon known biological mechanisms of action. With its experience to date, The company believe ProCellEx will enable it to develop additional proprietary recombinant proteins that are therapeutically superior to existing recombinant proteins currently marketed for the same indications. The company is now also applying the unique properties of its ProCellEx system for the oral delivery of therapeutic proteins. On May 1, 2012, the F...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to PLX / Protalix BioTherapeutics, Inc. on message board site Silicon Investor.

PLX Technology, Inc. (PLXT) Plexus Corporation (PLXS on NASDAQ)
PLX Technology Inc (PLXT) Simplex Solutions Inc. - SPLX
Mediaplex Inc-(MPLX) VIDEOPLEX OTCBB VPLX seeking merger or acquisition
Bio Plexus, Inc. BPLX Cerplex (cplx)
CUSIP: 74365A101